Page 7 - Pharmaceutical Sciences News Today

Initiating treatment with SGLT2 inhibitors vs GLP-1 RAs was linked to a 19% reduced risk for composite anemia outcomes in patients with T2D and CKD stages I-III.

Provost office pushes back playbook deadline

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 -- Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today...

Abceutics Inc., a startup preclinical-stage biopharmaceutical company spun out of a laboratory at the University at Buffalo, is being purchased as part of an up-to-$208 million agreement with biopharmaceutical giant

Despite having an overall survival rate of 94%, B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer, can prove challenging to treat, with survival among relapsed or resistant cases falling between 30-50%.

The University of Montana will welcome Matthew G. Fete as its new College of Health Dean on June 17. Fete most recently served as a professor at Chicago State University

The University of Montana has hired Dr. Matthew G. Fete as the next dean of its growing College of Health. He will start June 17.

The University of Montana has hired Dr. Matthew G. Fete as the next dean of its growing College of Health. He will start June 17.

The University of Montana has hired Dr. Matthew G. Fete as the next dean of its growing College of Health. He will start June 17.